Prof Michael Barry Clinical Director of the NCPE addressed the PMI on the cost effectiveness of medicines, along with the reimbursement process — a source of much continued debate in the Irish healthcare market.
The cost-containment in the area of pharmaceuticals will continue to be a priority for the HSE and looks to be an easy option for the health service, which is under pressure from the Department of Health, to balance its budget overrun for this year currently at €300m, the National Centre for Pharmaeconomics (NCPE) has warned.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
